Patents by Inventor Stephanie Allums-Donald

Stephanie Allums-Donald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymer-semaxanib moiety conjugates
    Patent number: 11007270
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 18, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • POLYMER-SEMAXANIB MOIETY CONJUGATES
    Publication number: 20200030451
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 30, 2020
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Polymer-semaxanib moiety conjugates
    Patent number: 10463744
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: November 5, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • POLYMER-SEMAXANIB MOIETY CONJUGATES
    Publication number: 20180185496
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 5, 2018
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Polymer-semaxanib moiety conjugates
    Patent number: 9943605
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 17, 2018
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Oligomer-tricyclic conjugates
    Patent number: 9725431
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Nektar Therapeutics
    Inventors: Wen Zhang, Xuyuan Gu, Stephanie Allums-Donald, Jennifer Riggs-Sauthier
  • Oligomer-containing hydantoin compounds
    Patent number: 9540330
    Abstract: The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 10, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald
  • OLIGOMER-TRICYCLIC CONJUGATES
    Publication number: 20140100268
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: September 6, 2013
    Publication date: April 10, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Wen Zhang, Xuyuan Gu, Stephanie Allums-Donald, Jennifer Riggs-Sauthier
  • Oligomer-Containing Hydantoin Compounds
    Publication number: 20140039020
    Abstract: The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Application
    Filed: December 15, 2011
    Publication date: February 6, 2014
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald
  • POLYMER-SEMAXANIB MOIETY CONJUGATES
    Publication number: 20140011855
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Application
    Filed: December 23, 2011
    Publication date: January 9, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson